Biomea Fusion (NasdaqGS:BMEA) - Share price, News & Analysis

BMEA fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

BMEA Stock Overview

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases.

Risk Analysis

Earnings are forecast to decline by an average of 2.9% per year for the next 3 years

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Biomea Fusion Competitors

Heron Therapeutics

NasdaqCM:HRTX

US$336.1m

Icosavax

NasdaqGS:ICVX

US$355.6m

C4 Therapeutics

NasdaqGS:CCCC

US$354.8m

Dyne Therapeutics

NasdaqGS:DYN

US$362.0m

Price History & Performance

Summary of all time highs, changes and price drops for Biomea Fusion
Historical stock prices
Current Share Price	US$12.03
52 Week High	US$16.28
52 Week Low	US$2.84
Beta	0
1 Month Change	107.06%
3 Month Change	169.73%
1 Year Change	-20.23%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-35.32%

Shareholder Returns

	BMEA	US Biotechs	US Market
7D	37.5%	10.3%	6.3%
1Y	-20.2%	-24.5%	-18.8%

Return vs Industry: BMEA exceeded the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: BMEA underperformed the US Market which returned -18.4% over the past year.

Price Volatility

Is BMEA's price volatile compared to industry and market?
BMEA volatility
BMEA Average Weekly Movement	20.8%
Biotechs Industry Average Movement	13.2%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.2%

Stable Share Price: BMEA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: BMEA's weekly volatility has increased from 15% to 21% over the past year.

About the Company

Founded	Employees	CEO	Website
2017	57	Thomas Butler	https://biomeafusion.com

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Biomea Fusion Fundamentals Summary

How do Biomea Fusion's earnings and revenue compare to its market cap?
BMEA fundamental statistics
Market Cap	US$350.90m
Earnings (TTM)	-US$52.08m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-6.7x

P/E Ratio

Is BMEA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMEA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$52.08m
Earnings	-US$52.08m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.79
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BMEA perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is BMEA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMEA?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for BMEA. This is calculated by dividing BMEA's market cap by their current preferred multiple.
What is BMEA's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$350.90m

BMEA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BMEA's PB Ratio compare to its peers?

BMEA PB Ratio vs Peers

The above table shows the PB ratio for BMEA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	4.4x
HRTX Heron Therapeutics	14x	59.2%	US$336.1m
ICVX Icosavax	1.4x	-2.4%	US$355.6m
CCCC C4 Therapeutics	1x	-20.7%	US$354.8m
DYN Dyne Therapeutics	1.1x	-19.0%	US$362.0m
BMEA Biomea Fusion	2.1x	-2.9%	US$350.9m

Price-To-Book vs Peers: BMEA is good value based on its Price-To-Book Ratio (2.1x) compared to the peer average (4.4x).

Price to Earnings Ratio vs Industry

How does BMEA's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: BMEA is expensive based on its Price-To-Book Ratio (2.1x) compared to the US Biotechs industry average (1.6x)

Price to Book Ratio vs Fair Ratio

What is BMEA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMEA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BMEA's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of BMEA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BMEA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BMEA's fair value for valuation analysis.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BMEA's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Biomea Fusion forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-2.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMEA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BMEA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BMEA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BMEA is forecast to have no revenue next year.

High Growth Revenue: BMEA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BMEA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Biomea Fusion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-383.2%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: BMEA is currently unprofitable.

Growing Profit Margin: BMEA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BMEA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BMEA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMEA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: BMEA has a negative Return on Equity (-31.61%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Biomea Fusion's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BMEA's short term assets ($167.0M) exceed its short term liabilities ($8.0M).

Long Term Liabilities: BMEA's short term assets ($167.0M) exceed its long term liabilities ($2.1M).

Debt to Equity History and Analysis

Debt Level: BMEA is debt free.

Reducing Debt: BMEA had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMEA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BMEA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 102.2% each year.

Discover healthy companies

Dividend

What is Biomea Fusion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMEA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMEA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMEA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMEA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMEA has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure

CEO

Thomas Butler (40 yo)

4.83yrs

Tenure

US$6,661,207

Compensation

Mr. Thomas Butler co-founded Biomea Fusion, Inc in August 2017 and has been its Chief Executive Officer and Director since August 2017. He serves as the Chairman of Biomea Fusion, Inc. He serves as a Manag...

CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD6.66M) is above average for companies of similar size in the US market ($USD2.83M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: BMEA's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Experienced Board: BMEA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/27 00:00
End of Day Share Price	2022/06/27 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31